Skip Navigation

Cardiovascular Research 1998 38(3):676-684; doi:10.1016/S0008-6363(98)00064-9
© 1998 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Weinbrenner, C.
Right arrow Articles by Cohen, M. V
Right arrow Search for Related Content
PubMed
Right arrow Articles by Weinbrenner, C.
Right arrow Articles by Cohen, M. V
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1998, European Society of Cardiology

Cyclosporine A limits myocardial infarct size even when administered after onset of ischemia

Christof Weinbrenner1, Guang S Liu, James M Downey and Michael V Cohen*

Departments of Physiology and Medicine, MSB 3050, University of South Alabama, College of Medicine, Mobile, AL 36688-0002, USA

* Corresponding author. Tel.: +1 (334) 460-6812; fax: +1 (334) 460-6464.

Objective: The role of the immunosuppressant cyclosporine A as a preconditioning-mimetic in the rabbit heart was examined. Methods: Cyclosporine A, a potent protein 2B or calcium/calmodulin-dependent phosphatase (PP) inhibitor, was administered to isolated rabbit hearts starting either 15 min prior to or 10 or 20 min after the onset of a 30 min period of regional ischemia and continuing until the onset of reperfusion. The effect of pretreatment with a second PP2B antagonist, FK-506, was also examined. In an additional protocol L-NAME was perfused for 50 min starting 5 min before the 45-min infusion of cyclosporine A. After 2 h of reperfusion infarct size was measured with triphenyltetrazolium chloride. In a second study left ventricular biopsies of isolated rabbit hearts were obtained to measure the effect of cyclosporine A on dephosphorylation of Formula phosphorylase kinase by calcium/calmodulin-dependent phosphatases. Results: Pretreatment with cyclosporine A resulted in only 10.0% infarction of the risk zone, significantly less than that in untreated control hearts (28.7%, p<0.001) but comparable to the extent of infarction in ischemically preconditioned hearts (10.0%, p<0.001 vs. control). Equivalent protection was also observed in hearts with treatment delayed for 10 min following the onset of ischemia (10.4% infarction, p<0.001 vs. control). However, protection waned when cyclosporine A was administered only during the last 10 min of the 30-min ischemic period (25.5% infarction, p=n.s. vs. control). Pretreatment with FK-506 also resulted in myocardial salvage (10.4% infarction, p<0.001 vs. control). When hearts were exposed to a co-infusion of L-NAME and cyclosporine A, protection was still evident (18.1% infarction, p<0.05 vs. L-NAME), although not as robust as that seen with the PP2B blocker alone. In hearts pretreated with cyclosporine A dephosphorylation of Formula phosphorylase kinase by calcium/calmodulin-dependent phosphatases was inhibited by 67%. Conclusions: Cyclosporine A and FK-506, potent PP2B inhibitors, can protect the ischemic rabbit heart, and at least cyclosporine A continues to be effective when infusion is delayed until after the onset of ischemia. The mechanism of this protection may be related to inhibition of phosphatases and prolongation of the phosphorylation state of ischemic cells.

KEYWORDS Ischemic preconditioning; Phosphorylation; Protein phosphatases; Cyclosporine A; FK-506; L-NAME; PP2B; Infarct size; Nitric oxide

1 Present address: Department of Cardiology, University of Heidelberg, Bergheimerstr. 58, D-69115 Heidelberg, Germany.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
A. Granfeldt, D. J. Lefer, and J. Vinten-Johansen
Protective ischaemia in patients: preconditioning and postconditioning
Cardiovasc Res, July 15, 2009; 83(2): 234 - 246.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
J. G. Krolikowski, M. Bienengraeber, D. Weihrauch, D. C. Warltier, J. R. Kersten, and P. S. Pagel
Inhibition of Mitochondrial Permeability Transition Enhances Isoflurane-Induced Cardioprotection During Early Reperfusion: The Role of Mitochondrial KATP Channels
Anesth. Analg., December 1, 2005; 101(6): 1590 - 1596.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
L. Gomez, N. Chavanis, L. Argaud, L. Chalabreysse, O. Gateau-Roesch, J. Ninet, and M. Ovize
Fas-independent mitochondrial damage triggers cardiomyocyte death after ischemia-reperfusion
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2153 - H2158.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R. Schulz, M. Kelm, and G. Heusch
Nitric oxide in myocardial ischemia/reperfusion injury
Cardiovasc Res, February 15, 2004; 61(3): 402 - 413.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
L. Argaud, O. Gateau-Roesch, L. Chalabreysse, L. Gomez, J. Loufouat, F. Thivolet-Bejui, D. Robert, and M. Ovize
Preconditioning delays Ca2+-induced mitochondrial permeability transition
Cardiovasc Res, January 1, 2004; 61(1): 115 - 122.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
D. M. YELLON and J. M. DOWNEY
Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology
Physiol Rev, October 1, 2003; 83(4): 1113 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
S. A Javadov, S. Clarke, M. Das, E. J Griffiths, K. H H Lim, and A. P Halestrap
Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart
J. Physiol., June 1, 2003; 549(2): 513 - 524.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
P. H. Sugden
Signaling in Myocardial Hypertrophy : Life After Calcineurin?
Circ. Res., April 2, 1999; 84(6): 633 - 646.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.